Study of Wolff-Parkinson-White syndrome by transesophageal pacing and assessment of long-term amiodarone therapy

Mario D. Gonzalez, Raul H. Guillen, Oscar A. Pellizzon, Elsa C. Raimondi

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Transesophageal atrial pacing has been used for the induction of supraventricular tachycardia (SVT) for diagnostic and therapeutic purposes.1 Recently, Critelli et al2 evaluated in 5 patients with the Wolff-Parkinson-White (WPW) syndrome, the effect of amiodarone administered during 1 month on induced atrial fibrillation and on the shortest cycle length with a 1:1 atrioventricular (AV) conduction over the accessory pathway. When an antiarrhythmic drug is administered, it is necessary to study the maximal response when steady-state tissue concentrations are reached. For this reason, amiodarone, which has an estimated half-life of about 40 days, should be evaluated after at least 2 or 3 half-lives. This report analyzes the use of transesophageal atrial pacing in the study of patients with WPW syndrome and the repeated assessment of the efficacy of long-term amiodarone administration.

Original languageEnglish (US)
Pages (from-to)852-856
Number of pages5
JournalThe American journal of cardiology
Volume55
Issue number6
DOIs
StatePublished - Mar 1 1985

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Study of Wolff-Parkinson-White syndrome by transesophageal pacing and assessment of long-term amiodarone therapy'. Together they form a unique fingerprint.

Cite this